Skip to main content
MSLE
NASDAQ Life Sciences

Satellos Bioscience Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Drug

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$7
Mkt Cap
$147.485M
52W Low
$5.44
52W High
$144
52W Position info
29% above low
Off High info
95% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

MSLE sits 29% above its 52-week low of $5.44.

Summary

Satellos Bioscience's SAT-3247, a drug candidate for Duchenne muscular dystrophy, has received FDA Fast Track designation, which will accelerate its development and regulatory review.


Key Events · Product Development and Regulatory · MSLE

  • FDA Fast Track Designation Granted

    SAT-3247 received Fast Track designation for Duchenne muscular dystrophy, recognizing its potential to address an unmet medical need.

  • Expedited Development and Review

    The designation allows for more frequent FDA interactions, rolling review, and potential eligibility for Accelerated Approval and Priority Review.

  • Ongoing Phase 2 Studies

    The company is currently advancing SAT-3247 through Phase 2 BASECAMP and TRAILHEAD studies, with additional data expected in the second half of 2026.

  • Builds on Prior Designations

    This adds to existing Orphan Drug and Rare Pediatric Disease designations for SAT-3247 in Duchenne muscular dystrophy.


Analysis · MSLE · Life Sciences

The FDA's Fast Track designation for SAT-3247 is a significant positive for Satellos Bioscience. This designation acknowledges the drug's potential to address a serious unmet medical need in Duchenne muscular dystrophy and will expedite its development and review process. This could lead to a faster path to market and increased interactions with the FDA, which is crucial for a clinical-stage biotechnology company.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MSLE was trading at $7.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $147.5M. The 52-week trading range was $5.44 to $144.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MSLE - Latest Insights

MSLE
Nov 06, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $6.00
Real-time Price: $7.19 info
Change: +$1.19 (+20%) info
Market Cap: $152.546M info
MSLE
Sep 30, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $8.60
Real-time Price: $7.19 info
Change: -$1.41 (-16%) info
Market Cap: $152.546M info
MSLE
Sep 24, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $8.91
Real-time Price: $7.19 info
Change: -$1.72 (-19%) info
Market Cap: $152.546M info
MSLE
Aug 13, 2026, 5:03 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $9.82
Real-time Price: $7.19 info
Change: -$2.63 (-27%) info
Market Cap: $152.546M info
MSLE
Jul 08, 2026, 6:30 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $8.37
Real-time Price: $7.19 info
Change: -$1.18 (-14%) info
Market Cap: $152.546M info